Barclays’s Strata Skin Sciences SSKN Stock Holding History

Barclays’s Portfolio SSKN Stock Details SSKN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-52	Closed	-$24K	–	7597
2013 Q2	$24K	Buy	+52	New	+$27.9K	﹤0.01%	6746

Other funds holding SSKN

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's SSKN Position: Q1 2020 in Review

Barclays sold out of Strata Skin Sciences (SSKN) in Q1 2020, closing a stake of 1 share.

Barclays first reported a position in SSKN in Q2 2013 and held it in 4 quarters. The position peaked at $25K in Q2 2013. 24 funds tracked by Wall St. Rank hold SSKN as of Q1 2020.

Barclays reported no remaining Strata Skin Sciences position as of Q1 2020 after selling out during the quarter.
Barclays sold 1 Strata Skin Sciences share in Q1 2020.
Barclays first reported a position in Strata Skin Sciences in Q2 2013 and held it in 4 quarters.
Barclays's Strata Skin Sciences position peaked at $25K in Q2 2013.
24 funds tracked by Wall St. Rank held Strata Skin Sciences as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.